Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunot
September 13 2023 - 7:30AM
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage
immuno-oncology company focused on the discovery and development of
next-generation therapeutics for cancer patients, today announced
it will present additional preclinical data on SNS-101, a
conditionally active, human monoclonal antibody targeting the
immune checkpoint VISTA (V-domain Ig suppressor of T cell
activation), at the Seventh Annual CRI-ENCI-AACR International
Cancer Immunotherapy Conference: Translating Science into Survival,
being held September 20 – 23, 2023 in Milan, Italy. The new
data build on SNS-101’s preclinical safety and efficacy profile and
provide additional insights into its conditionally active mechanism
of action. SNS-101 is currently in a Phase 1/2 clinical study.
Presentation Details:
Title: SNS-101, a clinical-stage pH-dependent
and TME-selective anti-VISTA antibody with favorable
pharmacokinetic and safety characteristics, promotes anti-tumoral
M1 macrophage polarization in PD-1 refractory settings
Presentation Type: Poster Date and
Time: Thursday, September 21, 2023, from 12:30 pm to 2:00
pm CETSession: Poster Session A
The poster will be made available on the Sensei Bio website
following the presentation.
About Sensei BiotherapeuticsSensei
Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology
company focused on the discovery and development of next-generation
therapeutics for cancer patients. Through its TMAb™ (Tumor
Microenvironment Activated biologics) platform, Sensei develops
conditionally active therapeutics designed to disable
immunosuppressive signals or activate immunostimulatory signals
selectively in the tumor microenvironment to unleash T cells
against tumors. Sensei’s lead investigational candidate is SNS-101,
a conditionally active antibody designed to block the V-domain Ig
suppressor of T cell activation (VISTA) checkpoint selectively
within the low pH tumor microenvironment, where VISTA acts as a
suppressor of T cells by binding the receptor PSGL-1. The company
is also developing SNS-102, a conditional binding monoclonal
antibody targeting V-Set and Immunoglobulin Domain Containing 4
(VSIG-4), as well as SNS-103, also a conditionally active
monoclonal antibody targeting ecto-nucleoside triphosphate
diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more
information, please visit www.senseibio.com, and follow the
company on Twitter @SenseiBio and LinkedIn.
Cautionary Note Regarding Forward-Looking
StatementsAny statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words and phrases such as “believe”, “designed to”,
“expect”, “may”, “plan”, “potential”, “will”, and similar
expressions, and are based on Sensei’s current beliefs and
expectations. These forward-looking statements include expectations
regarding the development, potential therapeutic benefits, and
potential safety profile of Sensei’s product candidates, including
SNS-101; and the presentation of new preclinical data for SNS-101.
These statements involve risks and uncertainties that could cause
actual results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include uncertainties inherent in the
development of therapeutic product candidates, such as the risk
that any one or more of Sensei’s product candidates will not be
successfully developed or commercialized; the risk of delay or
cessation of any planned clinical trials of Sensei’s product
candidates; the risk that prior results, such as signals of safety,
activity or durability of effect, observed from preclinical trials,
will not be replicated or will not continue in ongoing or future
studies or clinical trials involving Sensei’s product candidates;
the risk that Sensei’s product candidates or procedures in
connection with the administration thereof will not have the safety
or efficacy profile that we anticipate; risks associated with
Sensei’s dependence on third-party suppliers and manufacturers,
including sole source suppliers, over which we may not always have
full control; risks regarding the accuracy of our estimates of
expenses, capital requirements and needs for additional financing;
and other risks and uncertainties that are described in Sensei’s
Quarterly Report on Form 10-Q filed with the U.S. Securities and
Exchange Commission (SEC) on August 3, 2023 and Sensei’s other
Periodic Reports filed with the SEC. Any forward-looking statements
speak only as of the date of this press release and are based on
information available to Sensei as of the date of this release, and
Sensei assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Contact:Michael
BiegaSenior Director, Investor RelationsSensei
Biotherapeuticsmbiega@senseibio.com
Media Contact:Chris RaileyTen
Bridge Communicationschris@tenbridgecommunications.com
Sensei Biotherapeutics (NASDAQ:SNSE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sensei Biotherapeutics (NASDAQ:SNSE)
Historical Stock Chart
From Oct 2023 to Oct 2024